PMIDA-Modified Fe3O4 Magnetic Nanoparticles: Synthesis and Application for Liver MRI / A. M. Demin, A. G. Pershina, A. S. Minin [et al.]

Уровень набора: LangmuirАльтернативный автор-лицо: Demin, A. M., Aleksandr Mikhaylovich;Pershina, A. G., biologist, Associate Professor of Tomsk Polytechnic University, Candidate of biological sciences, 1981-, Aleksandra Gennadievna;Minin, A. S., Artem;Mekhaev, A. V., Alexander;Ivanov, V. V., Vladimir;Lezhava, S. P., Sofiya;Zakharova, A. A., Alexandra;Byzov, I. V., Iliya;Uimin, M. A., Mikhail;Krasnov, V. P., Victor;Ogorodova, L. M., LudmilaКоллективный автор (вторичный): Национальный исследовательский Томский политехнический университет, Исследовательская школа химических и биомедицинских технологий (ИШХБМТ), (2017- )Язык: английский.Страна: .Резюме или реферат: The surface modification of Fe3O4-based magnetic nanoparticles (MNPs) with N-(phosphonomethyl)iminodiacetic acid (PMIDA) was studied, and the possibility of their use as magnetic resonance imaging contrast agents was shown. The effect of the added PMIDA amount, the reaction temperature and time on the degree of immobilization of this reagent on MNPs, and the hydrodynamic characteristics of their aqueous colloidal solutions have been systematically investigated for the first time. It has been shown that the optimum condition for the modification of MNPs is the reaction at 40 °C with an equimolar amount of PMIDA for 3.5 h. The modified MNPs were characterized by X-ray diffraction, transmission electron microscopy, Fourier transform infrared spectroscopy, thermogravimetric, and CHN elemental analyses. The dependence of the hydrodynamic characteristics of the MNP colloidal solutions on the concentration and pH of the medium was studied by the dynamic light scattering method. On the basis of the obtained data, we can assume that the PMIDA molecules are fixed on the surface of the MNPs as a monomolecular layer. The modified MNPs had good colloidal stability and high magnetic properties. The calculated relaxivities r2 and r1 were 341 and 102 mmol-1 s-1, respectively. The possibility of using colloidal solutions of PMIDA-modified MNPs as a T2 contrast agent for liver studies in vivo (at a dose of 0.6 mg kg-1) was demonstrated for the first time..Примечания о наличии в документе библиографии/указателя: [References: 55 tit.].Аудитория: .Тематика: электронный ресурс | труды учёных ТПУ | магнитные наночастицы | магнитно-резонансная томография | коллоидные растворы | светорассеяние | контрастные средства Ресурсы он-лайн:Щелкните здесь для доступа в онлайн
Тэги из этой библиотеки: Нет тэгов из этой библиотеки для этого заглавия. Авторизуйтесь, чтобы добавить теги.
Оценка
    Средний рейтинг: 0.0 (0 голосов)
Нет реальных экземпляров для этой записи

Title screen

[References: 55 tit.]

The surface modification of Fe3O4-based magnetic nanoparticles (MNPs) with N-(phosphonomethyl)iminodiacetic acid (PMIDA) was studied, and the possibility of their use as magnetic resonance imaging contrast agents was shown. The effect of the added PMIDA amount, the reaction temperature and time on the degree of immobilization of this reagent on MNPs, and the hydrodynamic characteristics of their aqueous colloidal solutions have been systematically investigated for the first time. It has been shown that the optimum condition for the modification of MNPs is the reaction at 40 °C with an equimolar amount of PMIDA for 3.5 h. The modified MNPs were characterized by X-ray diffraction, transmission electron microscopy, Fourier transform infrared spectroscopy, thermogravimetric, and CHN elemental analyses. The dependence of the hydrodynamic characteristics of the MNP colloidal solutions on the concentration and pH of the medium was studied by the dynamic light scattering method. On the basis of the obtained data, we can assume that the PMIDA molecules are fixed on the surface of the MNPs as a monomolecular layer. The modified MNPs had good colloidal stability and high magnetic properties. The calculated relaxivities r2 and r1 were 341 and 102 mmol-1 s-1, respectively. The possibility of using colloidal solutions of PMIDA-modified MNPs as a T2 contrast agent for liver studies in vivo (at a dose of 0.6 mg kg-1) was demonstrated for the first time.

Для данного заглавия нет комментариев.

оставить комментарий.